MYLENE TRUONG to Protein Kinase Inhibitors
This is a "connection" page, showing publications MYLENE TRUONG has written about Protein Kinase Inhibitors.
Connection Strength
0.081
-
Targeted Therapy and Imaging Findings. J Thorac Imaging. 2017 Sep; 32(5):313-322.
Score: 0.051
-
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol. 2006 Sep 01; 24(25):4092-9.
Score: 0.024
-
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005 Apr 10; 23(11):2544-55.
Score: 0.005